| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 |
Form 4: Crystal Adam, President, R&D
Received 5,000 shares by exercise or conversion ($14.6K) · Sold 5,000 shares ($125K) |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in patients with 2L/3L ... |
| 09 Nov 2026 | 10-Q |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 |
Form 4: Crystal Adam, President, R&D
Received 5,000 shares by exercise or conversion ($14.6K) · Sold 5,000 shares ($112K) |
| 04 Nov 2026 |
Form 4: Newcomb Jessica, Principal Accounting Officer
Sold 7,031 shares ($158K) |
| 02 Nov 2026 | 144 |
| 23 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statem... |
| 05 Oct 2026 |
Form 4: Crystal Adam, President, R&D
Received 27,000 shares by exercise or conversion ($140K) · Sold 27,000 shares ($661K) |
| 24 Sep 2026 |
Form 4: Newcomb Jessica, Principal Accounting Officer
Sold 8,200 shares ($199K) |
| 22 Sep 2026 | 144 |
| 03 Sep 2026 |
Form 4: Crystal Adam, President, R&D
Received 27,000 shares by exercise or conversion ($140K) · Sold 27,000 shares ($604K) |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | SCHEDULE 13G/A |
Loading...